US heart group says COX 2 inhibitors should be last choice for pain relief in patients at risk

BMJ 2007; 334 doi: 10.1136/bmj.39139.644664.DB (Published 1 March 2007)
Cite this as: BMJ 2007;334:441.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Susan Mayor
  1. London

    Cyclo-oxygenase-2 (COX 2) inhibitors should be used only as the last choice after other types of non-steroidal anti-inflammatory drugs (NSAIDs) to relieve chronic pain in people with heart disease or at high risk of it, the American Heart Association has recommended. Its statement, which will be published this month in Circulation (http://circ.ahajournals.org), was designed to end any remaining confusion about the cardiovascular risk of these agents.

    The association has recommended a stepped approach to treatment. The first step should be non-pharmacological approaches, such as physical therapy and weight loss, for patients with known cardiovascular disease or with risk factors for ischaemic heart disease. Drug treatment should start with agents with the lowest …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL